Repligen: 3 Key Takeaways for Long-Term Investors
Repligen Corporation to Present at Jefferies Global Healthcare Conference
RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook
5 must-read analyst questions from Repligen’s Q3 earnings call
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Repligen To Issue $1B Of 0.25% Convertible Senior Notes Due 2031 As Part Of Exchange, With ~$541.4M Of New Notes Issued In Exchange For ~$456.8M Of 2028 Notes And ~$458.6M Of New Notes Issued For Cash
Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook
RBC Capital Maintains Outperform on Repligen, Raises Price Target to $200
Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance
Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)
Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss
Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In
Repligen Corporation Q3 2026 Earnings Call Summary
Repligen (RGEN) Q3 2026 Earnings Call Transcript
What Repligen (RGEN) Said on Its Q3 Earnings Call
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations
Repligen: Q3 Earnings Snapshot
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.